|Dr. Jason Scott Slakter||CEO, Pres & Director||220.19k||N/A||1958|
|Mr. Samuel Backenroth||CFO, VP of Bus. Devel. & Sec.||218.15k||N/A||1984|
|Dr. Glenn L. Stoller M.D.||Chief Scientific Officer||N/A||N/A||1964|
|Dr. Marlene Modi||Head of Preclinical & Regulatory Affairs||N/A||N/A||N/A|
OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
OHR Pharmaceutical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.